Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > Change of operational policy

<< Previous

Bullboard Posts

Next >>

Comment by moneycollectoron Dec 08, 2022 1:02pm

101 Views

Post# 35159576

RE:RE:RE:RE:RE:Change of operational policy

biorun wrote: September presentation: "Sirona will aim to finalize our partnership discussions for a right of first refusal prior to the commencement of the trial."

Who do you think they were in discussions with, themselves?

Sounds like the idea of a first right of refusal is not in the cards because they are doing this on their own terms, as noted today.

So either Sirona decided to go alone or this so called "first interest" left the table for some reasons.

<< Previous

Bullboard Posts

Next >>

Rig Count Soars as Utilization Surpasses Industry Averages